Venetoclax for the treatment of translocation (11;14) AL amyloidosisM Hasib Sidiqi, Prashant Kapoor, Abdullah S. Al Saleh et al.|Blood Cancer Journal|2020Cited by 54
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trialsM Hasib Sidiqi, Prashant Kapoor, Francis K. Buadi et al.|American Journal of Hematology|2021Cited by 35
Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma PatientsAbdullah S. Al Saleh, Shaji Kumar, Harsh Parmar et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 33
Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosisAbdullah S. Al Saleh, Morie A. Gertz, M Hasib Sidiqi et al.|American Journal of Hematology|2019Cited by 23
Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patientsAbdullah S. Al Saleh, Shaji Kumar, M Hasib Sidiqi et al.|American Journal of Hematology|2019Cited by 23